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Angiopoietins and Tie2 are angiogenic-speciﬁc ligand and receptor complex that have been shown to play a critical role in tumor
angiogenesis. Angiopoietin-2 (Ang2) is one of four ligands for receptor Tie2 and it is the naturally occurring antagonist to Tie2,
inhibiting the action of Angiopoietin-1 (Ang1). Over the last decade, signiﬁcant research has focused on elucidating the role of
Ang2 in cancer biology and its exact role in tumor angiogenesis remains elusive. In this study we have focused on establishing
the role of Ang2 in angiogenesis of malignant astrocytomas. We have demonstrated that Ang2 signiﬁcantly enhances the vascular
growth of malignant astrocytomas and constant upregulation of Ang2 throughout all phases of tumor growth generates abnormal
vascular structures that are not typically seen in human astrocytomas, suggesting that Ang2 plays a tumor stage-dependent role
and is not a consistently elevated throughout all growth stages of malignant astroctyomas.
1.Introduction
Based on the originally proposed paradigm by Holash et al.,
Angiopoietin-2 (Ang2) works in concert with VEGF to
promote neoangiogenesis, and in the absence of VEGF,
vessels that have been destabilized by Ang2 will undergo
apoptosis and regress. Ang2 is the naturally occurring
antagonist to Ang1 and inhibits Ang1-induced activation of
Tie2/TEK. Though there has been numerous biochemical
data to support this paradigm [1–7], there is suﬃcient data
to suggest a more complex role for Ang2. For example, at
high concentrations Ang2 acts as an agonist of Tie2/TEK,
providing a prosurvival signal to endothelial cell (EC), which
is a similar function as Ang1 [1]. Although all tumor
models show an upregulation of Ang2, its role in tumor
angiogenesis has proven to be quite complex and variable,
depending on the tumor model investigated [8–14]. Ang2
upregulation is seen primarily in EC of small cell lung
cancer, hepatocellular carcinoma, neuroblastoma, gastric
cancer, colon cancer, and Kaposi sarcoma, with Ang2 being
associated with poor prognosis in many of these tumors
[8–16].
Upregulation of Ang2 along with VEGF upregulation
suggests that vessel destabilization by Ang2 is a critical step
required to allow for VEGF-induced neoangiogenesis. In
astrocytomas, Ang2 has been found to be upregulated in
GBMs compared to LGAs and NB [11, 17–19]. The source
of Ang2 is mainly reported to be the EC; however, one study
and our own unpublished data suggest that Ang2 may also
be expressed by malignantly transformed astrocytoma cells
[11]. A noteworthy observation made by Stratmann et al. is
that expression of Ang2 appears to be vessel size- or vessel
type-dependent [20]. Ang2 expression was conﬁned to EC of
smaller vessels and not seen in larger vessels suggesting that
Ang2 promotes in-situ angiogenesis and is more intimately
involved with capillary-like vascular structures in tumors
[18, 20].
AmorerecentstudyidentiﬁesAng2asamarkeroftumor
cell invasion in high-grade astrocytomas, with little Ang2
expression seen in the center of human GBM compared
to the invasive peripheral edge of the tumors where Ang2
is expressed by both the vascular and neural elements
[13]. They also found that upregulation of Ang2 in U87
xenografts had a pronounced invasive phenotype compared2 Journal of Oncology
to the parental U87MG xenografts that had no Ang2
expression [13]. They propose that Ang2 confers a more
invasive phenotype to the tumor cells via either activation
of MMP-2, independent of Tie2/TEK receptor activation, or
perhaps via activation of integrins [13].
In this study, we have focused on deciphering the distinct
contribution of Ang2 to GBM angiogenesis and vessel devel-
opment. Wehavefound thatAng2 promotesvasculargrowth
of GBMs. Additionally, Ang2 induces vascular architectural
changes that are pathological and aberrant in comparison
to control tumor vessels. This aberrancy in vasculature is
not seen in human GBMs, which suggests that Ang2 is not
constantly upregulated in human tumors and alludes to a
stage-dependent upregulation of Ang2.
2.MaterialsandMethods
2.1. Cells and Reagents. Established human U87-MG GBM
c e l l sw e r eo b t a i n e df r o mA m e r i c a nT y p eC u l t u r eC o l l e c t i o n
(ATCC, Rockville, MD) and U373-MG cell lines were a
gift from B. Westermark (Uppsala, Sweden). These GBM
lines were chosen as they provide variability in their degree
of baseline Angiopoietin and VEGF-A expression [17], in
addition to variable tumorigenicity potential and diﬀerences
in genetic aberrations. They were maintained in Dulbecco’s
minimalessentialmedium(DMEM)(Cellgro,Herndon,VA)
supplemented with 10% FBS and penicillin-streptomycin
antibiotics.
2.2. Stable Clones
2.2.1. Constitutively Overexpressing Clones. Full-length hu-
man ANG2 cDNA (a gift from K. Alitalo, Helsinki, Finland)
was subcloned into the pSec vector (Invitrogen) to allow
generation of Myc-Histidine epitope-tagged constructs. The
Ang-Myc/HIS sequence was subcloned into the BamH1
and EcoR1 sites of the pCAGG vector that contained a
CMV promoter along with a chicken β-actin enhancer
element. Stable cell lines expressing Ang2, were generated by
transfection of the vector “pCAGG-Ang-Myc/HIS-Zeocin”
into U87 and U373 GBM lines using Lipofectamine 2000
(Gibco/BRL) as per the manufacturer’s instructions. Twenty
stable clones, selected with 1mg/ml of Zeocin (Invitrogen),
were examined for Ang2 expression by western blot analysis
asdescribedbelow.Twosinglecloneswithhighestexpression
of Ang2 above baseline parental levels, as well as one pooled
clone of Ang2 were selected for each of the three GBM lines
(U87:Ang2, U373:Ang2). Corresponding control stable cell
lines were generated using empty-vector transfectants.
2.2.2. Tetracycline Inducible Clones Overexpressing Angiopoi-
etins. As described previously, stable Tet-Oﬀ U87-MG cells
were established [21]. Brieﬂy, U87-MG cell lines were trans-
fected with pTet-Oﬀ (Clontech, Palo Alto) vector and stable
clones selected and maintained in 1mg/mL and 500μg/mL
of G418, respectively. Thirty of the Tet-Oﬀ clones were
assayed by transfecting with the reporter construct pTRE-
LUC and subsequent examination of luciferase activity with
a luciferase assay. The highest tetracycline inducible clone
w a ss e l e c t e dt og e n e r a t ed o u b l es t a b l eT e t - O ﬀ cell lines
(data not shown). Double stable Tet-Oﬀ U87-MG cell lines
overexpressing Ang2 were generated by cotransfecting U87-
MG:Tet-Oﬀ stable cells with pTRE-Ang2 with the pTK-
Puromycin vector. Stable clones were selected in 3mg/mL
of Puromycin, and twenty clones were tested for induction
of Ang2 expression by immunoprecipitation followed by
western blotting, as described below. For control U87-
MGTet-oﬀ double stable cell lines, pTRE-Red vector express-
ing the ds-RED ﬂuorescent protein was used. In vitro
testing of tetracycline induction of Ang2 expression was
determined using varying doses of Doxycycline, with the
most tightly regulated clones expressing Ang2 selected for in
vivo experiments.
2.3. In Vivo Tumor Models
2.3.1. Subcutaneous Models. Subcutaneous xenografts were
generated by growing U87-MG stable clones overexpressing
Ang2 in the ﬂanks of NOD-SCID mice. For each stable
clone, seven mice were injected with 107 cells suspended in
300μL of PBS, with ﬁve mice injected with control empty
vector transfectants. Tumor growth was measured biweekly,
using calipers by two observers in a blinded fashion. Tumor
volume was calculated using the formula: (diameter2×
length)/2. As per animal protocol, mice were sacriﬁced by
cervical dislocation after 100mg/kg BrDU injection (Sigma-
Aldrich). Tumors were cut in cross sections, with two
cross-sections kept in formaldehyde for paraﬃnb l o c k sa n d
immunohistochemical analysis and the remaining tumor
stored in liquid nitrogen. All in vivo tumor models were
repeated in duplicate.
2.3.2. Intracranial Models. For orthotopic xenograft models,
Tet-Oﬀ regulated human U87-MG:Ang2 cells (106)w e r e
stereotactically injected 3mm deep into the frontal cortex
of NOD-SCID mice. Mice were treated with Dox in the
drinking water with three doses of 0, 1, and 10mg/mL.
These doses were selected based on prior published studies
demonstrating that Dox crosses the blood-brain barrier
eﬃciently to regulate gene expression in the brain [21].
When animals exhibited symptoms consistent with failure
to thrive or raised intracranial pressure, the mice were
sacriﬁced by perfusion ﬁxation after BrDU injection and
tail vein injection of 2% Evans Blue solution (2mL/kg) to
determine intraluminal blood ﬂow and vessel permeability.
The time interval between the injection of Evans Blue and
the perfusion and killing of the mice was approximately 30
minutes. All in vivo experiments were repeated in duplicate.
2.4. Tumor Vascularity. Four diﬀerent tumor portions
w e r ee a c hc u ta t5 μmc o n s e c u t i v ep a r a ﬃns e c t i o n sa n d
stained with the EC speciﬁc marker anti-FactorVIII (DAKO;
1 : 2000), followed by detection with an avidin-biotin
complex method-3,3 -diaminobenzidine (VectaStain Elite;
VectorLaboratories)system.Microvesseldensity(MVD)was
calculated by counting the number of hollow lumen vesselsJournal of Oncology 3
in ten high-power ﬁelds (HPF:500x) and in ﬁve HPF at
vascular “hot spots”. Areas that included abnormal vascular
structures, such as glomeruloid bodies, were not included
in the MVD count as the functional status of these vascular
units in both human and xenograft tumors is not known.
All analyses were carried out using the MicroComputer
Image Device (MCID-Imaging Research, Inc.) linked to a
color CCD camera (Sony DXC 970 MD) mounted on a
transmitted-light microscope (Zeiss Axioskop). IHC for EC
and SMC staining was performed using FactorVIII antibody
and smooth muscle antigen (SMA) staining.
2.5. Immunohistochemistry. Standard hematoxylin and eosin
(H&E) staining and immunohistochemical analysis was
performed on 5μmt i s s u es e c t i o n sf r o mp a r a ﬃne m b e d -
ded tissue blocks. Primary antibodies used include: Fac-
torVIII (rabbit polyclonal antibody #A0082; DAKO; used at
1 : 2500) and a polyclonal goat anti-Ang2 antibody (1 : 200
and 1 : 400, Santa Cruz). Secondary antibody was a goat
antimouse antibody (Zymed) used at 1 : 200, and antigens
were detected using the avidin-biotin complex method
(Vector Laboratories) and diaminobenzidine substrate.
2.6. Statistical Analysis. All analyses were completed using
StatView 4.1 for the Macintosh (Abacus Concepts, Berkeley,
CA). All errors were calculated as the standard error of
the mean (S.E.M.). One-tailed Student’s t-test was used to
compare means (two sample, unequal variance) with P<. 05
considered statistically signiﬁcant.
3. Results
3.1. Overexpression of Ang2 in GBM Cell Lines. Parental
U87MGandU373MGcellshavenodetectableAng2(Figures
1(a) and 1(b))[ 17]. Overexpression of Ang2 did not alter
the in vitro proliferation rate, morphology, or the VEGF
expression of the cells compared to parental controls (data
not shown). Stable transfectants overexpressing the highest
levels of Ang2 (A2-1) and one pooled (A2-p) clone were
selected for subsequent experiments (Figures 1(a) and 1(b)).
Tet-Oﬀ regulated Ang2 stable clones were also established in
U87MG cells, with the most tightly regulated clones selected
for in vivo studies (Figure 1(c)). In the U87MG:Ang2 Tet-
Oﬀclone,Doxat5000ng/mLwassuﬃcienttodecreaseAng2
expression to undetectable levels, as seen in control cell lines
(Figure 1(c)).
3.2. Eﬀect of Ang2 on Tumor Growth and Proliferation.
We assessed the impact of Ang2 on the growth of GBM
xenografts in both subcutaneous (s.c). and intracranial
(i.c.) tumor models using stable cell lines of U87MG
and U373MG overexpressing Ang2 (Figure 1(b)). In s.c.
xenografts, Ang2 overexpression resulted in a signiﬁcantly
faster tumor growth and larger ﬁnal tumor size compared
to controls (Figure 1(b) and Table 1). In i.c. xenografts, Ang2
conferred a growth advantage as suggested by a signiﬁcant
decrease in survival and tumor proliferation (Figure 1(c)
and Table 2). The response to Ang2 was dose-dependent
with respect to survival, tumor proliferation, and vascularity
(Figure 1(c) and Table 2). Mice treated with 0mg/mL of
Dox in the drinking water, hence those with xenografts
expressing high levels of Ang2, had a signiﬁcantly shorter
survival time, and tumor proliferation was increased by 2.2-
fold compared to the mice receiving either 1 or 10mg/mL of
Dox, which had comparable survival to controls (Figure 1(c)
andTable 2).Ang2isnotexpressedendogenouslybyU87MG
cells (Figure 1(a)), therefore, addition of Dox can completely
turn-oﬀ exogenous Ang2 and result in similar tumor growth
a n ds u r v i v a lo fm i c ea st h a to fc o n t r o l s .
Ang2 upregulation resulted in increased MVD and
altered vessel size and EC distribution in both s.c. and i.c.
xenografts (Figure 2, Tables 1 and 2). Additionally, in both
s.c. and i.c. U87MG:Ang2 xenografts, there was an abnormal
vascular architecture, characterized by preponderance of
small vessels, “cord”-like distribution of EC and whirling
of EC present throughout the tumors, in addition to
increased numbers of dilated vessels (Figure 2(a)i and ii).
The alterations in the microvasculature were dependent on
levels of Ang2 expression that were regulated by Dox in the
i.c. U87MG:Ang2 models (Figure 1(b) and Table 1).A th i g h
levels of Ang2 (0mg/mL Dox), a large number of dilated
vessels were present, along with abnormal EC distribution
throughout the tumor (Figure 2(b)). With Dox suppression
(10mg/mL Dox) of Ang2, EC distribution, vessel size, and
the overall microvasculature architecture returned to similar
structural patterns as is seen in control U87MG tumors
(Figure 2(b)andTable 2).Thesevascularalterationshavenot
been reported previously; though the recent publication by
Hu et al. [13] and Lee et al. [19] makes the observation of
impaired angiogenesis by Ang2, they do not report similar
structural changes as ours on tumor vascularity.
4. Discussion
Astrocytomas angiogenesis is postulated to be highly tumor
stage-dependant. At their initial growth phase, they coopt
and parasitize existing host vessels in an attempt to support
their growth, thus the ﬁrst phase being independent of the
tumor angiogenic process [18, 22–24]. The second growth
phase begins when the host mounts a defensive response and
the parasitized vascular supply regresses resulting in tumor
hypoxia and necrosis, which in turn triggers upregulation of
Ang2 and VEGF [23, 24]. Therefore, Ang2 appears to play a
highly phase-dependent role in the progression of malignant
astrocytomas. It plays a pivotal role in the cooption of
host vessels in the initial phase; and in supporting in-
situ tumor angiogenesis, while in the second phase it
allows destabilization of mature vessels, by antagonizing
Ang1-mediated Tie2/TEK activation, in order to facilitate
mitogenic stimulation of ECs by VEGF and promoting
tumorneovascularization[22,24].However,theroleofAng2
in tumor angiogenesis remains controversial.
We have found that Ang2 upregulation, in both s.c. and
i.c. xenografts, led to an increase in growth rate, ﬁnal volume
and proliferation of GBMs along with an increase in tumor
angiogenesis. Ang2 upregulation resulted in an alteration of
vascular structures, marked by abnormal EC distribution,4 Journal of Oncology
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Figure 1: Eﬀect of Ang2 over-expression on growth of GBM xenografts. Stable clones of U87 and U373 were generated to over-express Ang2
constitutively. Neither of the cell lines expresses Ang2 at baseline. One highest expressing clone and one pooled clone of each cell line was
grown as subcutaneous models. Ang2 restricted tumor growth in U373 (a) tumors while it conferred a growth advantage in U87 tumors (b).
Similarly, a growth advantage was maintained in U87 intracranial xenografts as evidenced by a signiﬁcantly lowered survival time of mice
with these grafts compared to mice with control tumors, and this increased tumor growth was dose dependent on Ang2 (c).Journal of Oncology 5
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Figure 2: Eﬀect of Ang2 on tumor vascularity. Immunohistochemical analysis of tumor vessels as determined by Factor VIII stains was
performed on Ang2 upregulated xenografts. (a) i) subcutaneous and ii) intracranial tumors of U87MG:Ang2 demonstrated in addition
to an increase in MVD, abnormal EC distribution with ﬁne “cord” like-structures dispersed throughout the tumor, areas of EC whirling
(inset ii) and dilated vessels. This process was seen in both the intracranial and subcutaneous xenografts and was dependent on the level of
Ang2 expression. (b) Tumors with high levels of Ang2 expression (No Dox in the drinking water) had a small, highly inﬁltrative EC pattern
together with dilated vessels, whereas these structural changes are lost with turning oﬀ of Ang2 using 1mg/mL, and to a greater extent at
10mg/mL, of Dox in the drinking water.
Table 1: Eﬀect of Ang2 on subcutaneous xenograft models of GBM.
U87MG:Ctl U87MG:Ang2 U373:Ctl U373MG:Ang2
n = 8 n = 15 n = 15 n = 15
Final Tumor Size (cm3)
2.01 5.7 ∗ 3.18 5.96
(SEM 0.3) (SEM 0.4) (SEM 0.3) (SEM 0.5)
P = 4 × 10
−4 P = 6 ×10
−5
Proliferation Index 0.23 0.75∗ 0.042 0.28
P = .0042 P = .001
MVD (vessels/HPF) mean of 10 counts
2.12 9.5∗ 33 . 9 ∗
(SEM 0.1) (SEM 0.1) (SEM 0.1) (SEM 0.2)
P = .001 P = .001
SEM = Standard Error of Mean
∗indicates statistical signiﬁcance.
with EC forming “cord” or capillary-like structures and areas
of EC whorling present throughout the tumor, in addition
to a high number of dilated vessels. In the model used in
thisstudy,thereisconstantupregulationofAng2throughout
all stages and phase of GBM tumor growth, potentially
providing a continual trigger for host vessel cooption and
promoting in-situ angiogenesis, thereby increased tumor
growth.
On the other hand, Lee et al. have demonstrated a
complex temporal and stage-dependent role for Ang2 [19].6 Journal of Oncology
Table 2: Eﬀect of Ang2 on intracranial U87MG xenografts.
U87MG:Ctl U87MG:Ang2
no. Dox. 1mg/mL Dox 10mg/mL Dox
n = 10 n = 10 n = 10 n = 10
Overall survival (days)
63.7 54.7∗ 71.7∗ 74.4
(SEM = 2.3) (SEM = 3.3) (SEM = 2.3) (SEM = 3.5)
P = .015 P = .021 P = .0149
Proliferation index
0.043 0.094∗ 0.038∗ 0.035∗
(SEM = 0.01) (SEM = 0.01) (SEM = 0.00) (SEM = 0.00)
P = .0039 P = .3989 P = .4262
MVD (vessels/HPF) mean of 10 counts
5.8 8.8∗ 4.6∗ 4.0∗
(SEM = 0.478) (SEM = 0.859) (SEM = 0.616) (SEM = 0.785)
P = .0132 P = .038 P = .0189
They observe a bimodal expression pattern of Ang2 in
astrocytomas and support the postulate that Ang2 is a
vessel destabilize, seen at sites of tumor cell growth, tumor
periphery, and around sites of necrosis, presumably to
promote neoangiogenesis and support tumor cell growth
[19]. However, quite contrary to what one would predict
based on this observation, Lee et al. also found that Ang2
treatment of U87MG xenografts did not promote but rather
restrictedastrocytomagrowth.Moreover,atﬁrstglancethese
results appear to be in opposition with our observations;
however, on closer analysis, both ﬁndings can be seen
as corroborative and together explain the complex tumor
phase-dependent role of Ang2. Lee et al. treated the U87MG
i.c. xenografts on day 4 after tumor implantation followed
by biweekly injections of Ang2, whereas in our model Ang2
is upregulated constantly throughout all stages of tumor
growth. The diﬀerence between the level and stages of Ang2
upregulation in the two models supports the postulate that
Ang2 plays a highly tumor stage-dependent role. Another
evidentiary data that Ang2 plays a stage dependent role in
gliomaangiogenesisisthefactthattumorvascularstructures
observed in our xenograft models are not evident in human
GBM specimens, indicating that Ang2 is not upregulated
throughout all stages of human GBMs, and most likely plays
a very precise role at speciﬁc stages of GBM growth.
ThemechanismbywhichAng2causesabnormalvascular
structures is not established. The abundant “cord” or
capillary-like vessels in the U87MG:Ang2 xenografts may
be a result of Ang2-mediated modulation of EC motility,
migration, and invasion. Hu et al. demonstrate regions of
Ang2-expressing tumors actively invading the brain, high
levels of MMP-2 expression, and increased angiogenesis.
The direct impact of Ang2 on EC invasion in vivo remains
unknown.
Additionally, Ang2 is known to inﬂuence the fate of new
tumor vessels, diﬀerentiating them into capillaries versus
arteries or venous structures. We observe dilated vessels
throughouttheGBMxenografts.Themostlikelyexplanation
is that Ang2 presents an inhibitory signal, preventing Ang1-
mediated maturation by of the newly formed tumor vessels.
Taken together our data indicates that increased Ang2 pro-
motes angiogenic growth of GBMs. Constant upregulation
of Ang2 throughout all phases of tumor growth results in
the abnormal vascular structures seen in our xenografts
that are not present in human GBMs, suggesting that Ang2
upregulationinGBMsisverymuchatumorstagedependent
process and not constant throughout all stages of GBM
growth. Future studies are required to decipher the precise
temporalroleofAng2andwhetherthecombinatorialimpact
of other angiogenic cytokines with Ang2 can be used for
therapeutic targets in treatment of GBMs.
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